Jefferies released a research report stating that DAMAI ENT (01060) issued a positive profit alert for the first half of fiscal year 2026, with expected profits of no less than RMB 500 million, surpassing market and the firm's forecasts. This growth was primarily driven by strong performance in the Aliyu business. Jefferies maintained a "Buy" rating with a target price of HK$1.4.

The report highlighted that the profit growth was fueled by several factors, including outstanding performance in the Aliyu segment, which recorded robust year-on-year increases in both revenue and profit, as well as improved asset structure. DAMAI ENT emphasized the sustained healthy growth of its core business operations and plans to leverage its cash reserves to expand its presence in the diversified entertainment sector.